LG55

LG55 is an early-stage biotechnology company focused on the development of novel metabolic therapies. The company is primarily engaged in the discovery and advancement of dual agonists targeting the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR). These programs are designed to address high-unmet needs in obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). By leveraging expertise in peptide and small molecule chemistry, LG55 aims to create next-generation metabolic regulators with improved efficacy and safety profiles. The company operates primarily in the pre-clinical space, working toward identifying lead candidates for clinical entry.